Chris Cooley
Stock Analyst at Stephens & Co.
(3.09)
# 1,228
Out of 5,113 analysts
55
Total ratings
71.05%
Success rate
44.18%
Average return
Main Sectors:
Stocks Rated by Chris Cooley
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| VCEL Vericel | Maintains: Overweight | $39 → $42 | $36.20 | +16.02% | 2 | May 11, 2023 | |
| ALGN Align Technology | Maintains: Overweight | $500 → $375 | $164.92 | +127.38% | 7 | Jul 28, 2022 | |
| COO The Cooper Companies | Maintains: Overweight | $125 → $115 | $80.48 | +42.89% | 9 | Jun 3, 2022 | |
| ALC Alcon | Upgrades: Overweight | $86 → $92 | $80.42 | +14.40% | 4 | May 12, 2022 | |
| PLSE Pulse Biosciences | Maintains: Overweight | $14 → $12 | $13.55 | -11.44% | 2 | Apr 1, 2022 | |
| ANIK Anika Therapeutics | Downgrades: Equal-Weight | n/a | $9.13 | - | 2 | Mar 9, 2022 | |
| ESTA Establishment Labs Holdings | Maintains: Overweight | $88 → $90 | $67.18 | +33.97% | 3 | Nov 10, 2021 | |
| STE STERIS | Maintains: Overweight | $255 → $270 | $260.86 | +3.50% | 5 | Nov 4, 2021 | |
| GKOS Glaukos | Upgrades: Overweight | $60 → $68 | $123.94 | -45.13% | 5 | Nov 3, 2021 | |
| AVNS Avanos Medical | Downgrades: Equal-Weight | $60 → $45 | $12.85 | +250.19% | 2 | Aug 4, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $425 → $275 | $105.33 | +161.08% | 5 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $56 → $37 | $19.15 | +93.21% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $75 → $60 | $73.36 | -18.21% | 3 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $48 → $35 | $93.79 | -62.68% | 2 | Mar 23, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Equal-Weight | $60 → $81 | $258.20 | -68.63% | 2 | Feb 22, 2018 |
Vericel
May 11, 2023
Maintains: Overweight
Price Target: $39 → $42
Current: $36.20
Upside: +16.02%
Align Technology
Jul 28, 2022
Maintains: Overweight
Price Target: $500 → $375
Current: $164.92
Upside: +127.38%
The Cooper Companies
Jun 3, 2022
Maintains: Overweight
Price Target: $125 → $115
Current: $80.48
Upside: +42.89%
Alcon
May 12, 2022
Upgrades: Overweight
Price Target: $86 → $92
Current: $80.42
Upside: +14.40%
Pulse Biosciences
Apr 1, 2022
Maintains: Overweight
Price Target: $14 → $12
Current: $13.55
Upside: -11.44%
Anika Therapeutics
Mar 9, 2022
Downgrades: Equal-Weight
Price Target: n/a
Current: $9.13
Upside: -
Establishment Labs Holdings
Nov 10, 2021
Maintains: Overweight
Price Target: $88 → $90
Current: $67.18
Upside: +33.97%
STERIS
Nov 4, 2021
Maintains: Overweight
Price Target: $255 → $270
Current: $260.86
Upside: +3.50%
Glaukos
Nov 3, 2021
Upgrades: Overweight
Price Target: $60 → $68
Current: $123.94
Upside: -45.13%
Avanos Medical
Aug 4, 2021
Downgrades: Equal-Weight
Price Target: $60 → $45
Current: $12.85
Upside: +250.19%
Mar 23, 2020
Maintains: Overweight
Price Target: $425 → $275
Current: $105.33
Upside: +161.08%
Mar 23, 2020
Maintains: Overweight
Price Target: $56 → $37
Current: $19.15
Upside: +93.21%
Mar 23, 2020
Maintains: Overweight
Price Target: $75 → $60
Current: $73.36
Upside: -18.21%
Mar 23, 2020
Maintains: Overweight
Price Target: $48 → $35
Current: $93.79
Upside: -62.68%
Feb 22, 2018
Maintains: Equal-Weight
Price Target: $60 → $81
Current: $258.20
Upside: -68.63%